Navigation Links
Rutgers research tackles childhood epilepsy

NEW BRUNSWICK, N.J. Rutgers researchers have discovered a potential new way to treat childhood epilepsy using a widely available therapeutic drug.

Rutgers neuroscientist Gabriella D'Arcangelo and her colleagues have published their research findings in the journal Disease Models and Mechanisms (in press) and the paper has just appeared online.

In their quest for new therapeutic approaches, the researchers are investigating the molecular basis of the disease. The article describes the first use of a mouse model of cortical dysplasia, a malformation of the brain that is most often the cause of childhood epilepsy. Introducing the drug rapamycin, originally used to prevent rejection in organ transplants, suppressed epileptic seizures in the mice.

Epilepsy is the third most common neurological disorder in the United States after Alzheimer's disease and stroke. It currently affects more than 326,000 children under age 15. More than 90,000 of them have severe seizures that cannot be adequately treated. The children often go on to develop cognitive problems due to recurrent and uncontrolled seizures and the combined effects of heavy medication. They may also suffer consequences from having parts of their brains removed during surgery.

According to the International League Against Epilepsy (ILAE), approximately 45 percent of the pediatric epilepsy surgery cases (patients under age 18) are due to cortical dysplasia. A staggering 75 percent of surgery patients under age 2 have the condition.

"The surgery is not without risks, and while it may help control the seizures, it does not work in all cases," said D'Arcangelo, an associate professor in the Department of Cell Biology and Neuroscience at Rutgers, The State University of New Jersey. "Clearly there is a pressing need to come up with new strategies for treatment."

D'Arcangelo's mutant mice lack a gene (Pten) that suppresses cell growth in some neurons, resulting in these mutants displaying molecular, cellular and physiological traits of cortical dysplasia. The researchers treated the mice with rapamycin. It had already shown promise in a different mouse model for treating tuberous sclerosis complex (TSC), a subtype of cortical dysplasia.

"We demonstrated that rapamycin is a novel and effective anti-epileptic agent that suppresses seizures in our mice, as well as in the TSC model, and this has raised some hope for the future," said D'Arcangelo. "This drug is being tested on human patients of tuberous sclerosis in a multicenter study involving six TSC clinics throughout the United States. I hope it will soon be tested for all cortical dysplasia patients."


Contact: Joseph Blumberg
732-932-7084 x652
Rutgers University

Related biology news :

1. Rutgers study finds many consumers ignore food product recalls
2. Evolution and climate change research advances at Rutgers-Camden
3. Rutgers receives US$10 million to establish Institute for Food, Nutrition and Health
4. Rutgers scholar authors definitive biography of reproductive medicine pioneer
5. No helicopter moms among Rutgers mutant mice
6. $3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells
7. Rutgers biologist to study worms in Amazon, glaciers
8. Better protection for biomedial devices could result from Rutgers-Camden research
9. Raydiance collaborates with Rutgers, MTF to develop innovative tissue processing approaches
10. USDA Cooperative Agreement funds mosquito project at Rutgers
11. Rutgers scientists research reveals critical knowledge about the nervous system
Post Your Comments:
Related Image:
Rutgers research tackles childhood epilepsy
(Date:10/12/2015)... 2015 NXTD ) ("NXT-ID" or the ... commerce market, reports on the recent SNS Future in Review ... --> NXTD ) ("NXT-ID" or the "Company"), a biometric ... on the recent SNS Future in Review Conference in ... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/6/2015)... 6, 2015 Track Group, Inc. (OTCQX: TRCK), ... has signed a contract with the Virginia Department of ... range of sentences under the Department,s oversight. ... "This contract with the Virginia DOC will expand our ... advances our position as a trusted leader in offender ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... and commercializing novel treatments in oncology, endocrinology and women,s ... , the Company,s former Senior Vice President, Chief Financial ... Quebec City office.  David ... of the Company commented, "After a comprehensive review, the ...
(Date:10/12/2015)... , Belgium , Oct. 12, 2015 /PRNewswire/ ... that full results from a completed clinical study of its ... have been published in the online issue of Clinical ... The peer-reviewed study was conducted in collaboration with ... led by Roland Andersson , MD, PhD, Professor of ...
(Date:10/11/2015)... ... October 11, 2015 , ... Intelligent Implant Systems, LLC is ... multiple surgeries have been completed with this new posterior thoracolumbar spinal fusion system. ... Center of the Carolinas. The Revolution™ Spinal System pioneers a new approach ...
(Date:10/9/2015)... 9, 2015 Governor Tom Wolf ... company focused on developing T-cell receptor cancer immunotherapy treatments, ... a new expansion project. Pennsylvania ... commonwealth as 110 new, high-paying jobs will be created ... "My budget proposal includes sustained funding for the life ...
Breaking Biology Technology: